Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.

You may also be interested in...

Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy

Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.

Ramucirumab Becomes First Lilly ImClone Compound To Enjoy Phase III Success

The VEGF2-inhibitor demonstrated an overall survival benefit and prolonged progression-free survival in second-line gastric cancer, Lilly said. The big pharma acquired ramucirumab through its $6.5 billion purchase of ImClone Systems in 2008.

Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial

Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts